Real-World data shows Tirabrutinib's promise for rare brain cancer
NCT ID NCT06714370
First seen May 26, 2026 · Last updated Jun 11, 2026 · Updated 5 times
Summary
This study looked at 24 adults in Taiwan with a rare brain lymphoma that came back or didn't respond to treatment. Researchers checked how well the drug tirabrutinib worked and what side effects occurred in everyday medical practice, not a strict research lab. The goal was to see how many patients had their tumors shrink or disappear.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA (PCNSL) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Chang Gung Memorial Hospital
Kaohsiung City, Taiwan
-
Chang Gung Memorial Hospital
Taoyuan, Taiwan
-
China Medical University Hospital
Taichung, Taiwan
-
National Cheng Kung Univeristy Hospital
Tainan, Taiwan
-
National Taiwan University Hospital
Taipei, Taiwan
-
Taipei Veterans General Hospital
Taipei, Taiwan
Conditions
Explore the condition pages connected to this study.